REFERENCES
- Abdollahi T., Robertson N. M., Abdollahi A., Litwack G. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Cancer Res 2003; 63: 4521–4526, [INFOTRIEVE], [CSA]
- Ahonen M., Poukkula M., Baker A. H., Kashiwagi M., Nagase H., Eriksson J. E., Kahari V. M. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 2003; 22: 2121–2134, [INFOTRIEVE], [CSA], [CROSSREF]
- Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002; 2: 420–430, [INFOTRIEVE], [CSA], [CROSSREF]
- Ashkenazi A., Dixit V. M. Death receptors: signaling and modulation. Science 1998; 281: 1305–1308, [INFOTRIEVE], [CSA], [CROSSREF]
- Beatty G. L., Paterson Y. IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J. Immunol 2000; 165: 5502–5508, [INFOTRIEVE], [CSA]
- Bennett M. W., O'Connell J., O'Sullivan G. C., Brady C., Roche D., Collins J. K., Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol 1998; 160: 5669–5675, [INFOTRIEVE], [CSA]
- Bhowmick N. A., Neilson E. G., Moses H. L. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332–337, [INFOTRIEVE], [CSA], [CROSSREF]
- Bodmer J. L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., Blenis J., Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol 2000; 2: 241–243, [INFOTRIEVE], [CSA], [CROSSREF]
- Bosque A., Pardo J., Martinez-Lorenzo M. J., Lasierra P., Larrad L., Marzo I., Naval J., Anel A. Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL. Eur. J. Immunol 2005; 35: 1812–1821, [INFOTRIEVE], [CSA], [CROSSREF]
- Bouralexis S., Findlay D. M., Evodokiou A. Death to the bad buy: targeting cancer via Apo2L/TRAIL. Apoptosis 2005; 10(1)35–51, [INFOTRIEVE], [CSA], [CROSSREF]
- Chen Q., Evans S. S. Thermal regulation of lymphocyte trafficking: hot spots of the immune response. Int. J. Hyperthermia 2005; 21: 723–729, [INFOTRIEVE], [CSA], [CROSSREF]
- Chen Q., Wang W. C., Evans S. S. Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol. Immunother 2003; 52: 670–679, [INFOTRIEVE], [CSA], [CROSSREF]
- Cheng J., Hylander B. L., Baer M. R., Chen X., Repasky E. A. Multiple mechanisms underlie resistance of leukemia cells to Apo2L/TRAIL. Molec. Can. Ther 2006, (in press)[CSA]
- Coussens L. M., Tinkle C. L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481–490, [INFOTRIEVE], [CSA], [CROSSREF]
- Coussens L. M., Werb Z. Inflammation and cancer. Nature 2002; 420: 860–867, [INFOTRIEVE], [CSA], [CROSSREF]
- Curnis F., Sacchi A., Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest 2002; 110: 475–482, [INFOTRIEVE], [CSA], [CROSSREF]
- Di Pietro R., Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/ Apo2L. J. Cell. Physiol 2004; 201: 331–340, [INFOTRIEVE], [CSA], [CROSSREF]
- Dorothee G., Vergnon I., Menez J., Echchakir H., Grunenwald D., Kubin M., Chouaib S., Mami-Chouaib F. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/ TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J. Immunol 2002; 169: 809–817, [INFOTRIEVE], [CSA]
- Emery J. G., McDonnell P., Burke M. B., Deen K. C., Lyn S., Silverman C., Dul E., Appelbaum E. R., Eichman C., DiPrinzio R., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem 1998; 273: 14363–14367, [INFOTRIEVE], [CSA], [CROSSREF]
- Gross A., Yin X. M., Wang K., Wei M. C., Jockel J., Milliman C., Erdjument-Bromage H., Tempst P., Korsmeyer S. J. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem 1999; 274: 1156–1163, [INFOTRIEVE], [CSA], [CROSSREF]
- He Y. F., Wang X. H., Zhang G. M., Chen H. T., Zhang H., Feng Z. H. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol. Immunother 2005; 54: 891–897, [INFOTRIEVE], [CSA], [CROSSREF]
- Hurwitz H., Fehrenbacher L., Novotny W., cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med 2004; 350: 2335–2342, [INFOTRIEVE], [CSA], [CROSSREF]
- Hylander B. L., Pitoniak R., Penetrante R. B., Gibbs J. F., Oktay D., Cheng J., Repasky E. A. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J. Transl. Med 2005; 3: 22, [INFOTRIEVE], [CSA], [CROSSREF]
- Ikeda H., Old L. J., Schreiber R. D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95, [INFOTRIEVE], [CSA], [CROSSREF]
- Jain R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med 2001; 7: 987–989, [INFOTRIEVE], [CSA], [CROSSREF]
- Jain R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62, [INFOTRIEVE], [CSA], [CROSSREF]
- Jin Z., McDonald E. R., 3rd, Dicker D. T., El-Deiry W. S. Deficient TRAIL death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem 2004; 279: 35829–35839, [INFOTRIEVE], [CSA], [CROSSREF]
- Johansson N., Ahonen M., Kahari V. M. Matrix metalloproteinases in tumor invasion. Cell Mol. Life Sci 2000; 57: 5–15, [INFOTRIEVE], [CSA], [CROSSREF]
- Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med 1999; 189: 1451–1460, [INFOTRIEVE], [CSA], [CROSSREF]
- Kim K., Wilson S. M., Abayasiriwardana K. S., Collins R., Fjellbirkeland L., Xu Z., Jablons D., Nishimura S. L., Broaddus C. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am. J. Respir. Cell Mol. Biol 2005; 33: 541–548, [INFOTRIEVE], [CSA], [CROSSREF]
- Kim M., Park S. Y., Pai H. S., Kim T. H., Billiar T. R., Seol D. W. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Cancer Res 2004; 64: 4078–4081, [INFOTRIEVE], [CSA], [CROSSREF]
- Kischkel F. C., Lawrence D. A., Chuntharapai A., Schow P., Kim K. J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611–620, [INFOTRIEVE], [CSA], [CROSSREF]
- LeBlanc H. N., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell. Death Differ 2003; 10: 66–75, [INFOTRIEVE], [CSA], [CROSSREF]
- Lee S. H., Shin M. S., Kim H. S., Lee H. K., Park W. S., Kim S. Y., Lee J. H., Han S. Y., Park J. Y., Oh R. R., et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001; 20: 399–403, [INFOTRIEVE], [CSA], [CROSSREF]
- Lee Y. J., Moon M. S., Kwon S. J., Rhee J. G. Hypoxia and low glucose differentially augments TRAIL-induced apoptotic death. Mol. Cell Biochem 2005; 270: 89–97, [INFOTRIEVE], [CSA], [CROSSREF]
- Li H., Zhu H., Xu C. J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491–501, [INFOTRIEVE], [CSA], [CROSSREF]
- Limb G. A., Matter K., Murphy G., Cambrey A. D., Bishop P. N., Morris G. E., Khaw P. T. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am. J. Pathol 2005; 166: 1555–1563, [INFOTRIEVE], [CSA]
- Liu X. W., Taube M. E., Jung K. K., Dong Z., Lee Y. J., Roshy S., Sloane B. F., Fridman R., Kim H. R. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005; 65: 898–906, [INFOTRIEVE], [CSA]
- Martinez-Lorenzo M. J., Alava M. A., Gamen S., Kim K. J., Chuntharapai A., Pineiro A., Naval J., Anel A. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol 1998; 28: 2714–2725, [INFOTRIEVE], [CSA], [CROSSREF]
- Maxwell P. H., Dachs G. U., Gleadle J. M., Nicholls L. G., Harris A. L., Stratford I. J., Hankinson O., Pugh C. W., Ratcliffe P. J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 1997; 94: 8104–8109, [INFOTRIEVE], [CSA], [CROSSREF]
- Miyashita T., Kawakami A., Nakashima T., Yamasaki S., Tamai M., Tanaka F., Kamachi M., Ida H., Migita K., Origuchi T., et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin. Exp. Immunol 2004; 137: 430–436, [INFOTRIEVE], [CSA], [CROSSREF]
- Naka T., Sugamura K., Hylander B. L., Widmer M. B., Rustum Y. M., Repasky E. A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800–5806, [INFOTRIEVE], [CSA]
- Neville-Webbe H. L., Cross N. A., Eaton C. L., Nyambo R., Evans C. A., Coleman R. E., Holen I. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res. Treat 2004; 86: 269–279, [INFOTRIEVE], [CSA], [CROSSREF]
- Nyormoi O., Mills L., Bar-Eli M. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 2003; 10: 558–569, [INFOTRIEVE], [CSA], [CROSSREF]
- Okada K., Komuta K., Hashimoto S., Matsuzaki S., Kanematsu T., Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin. Cancer Res 2000; 6: 3560–3564, [INFOTRIEVE], [CSA]
- Olumi A. F., Grossfeld G. D., Hayward S. W., Carroll P. R., Tlsty T. D., Cunha G. R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002–5011, [INFOTRIEVE], [CSA]
- Ozoren N., Fisher M. J., Kim K., Liu C. X., Genin A., Shifman Y., Dicker D. T., Spinner N. B., Lisitsyn N. A., El-Deiry W. S. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol 2000; 16: 917–925, [INFOTRIEVE], [CSA]
- Pan G., Ni J., Wei Y. F., Yu G., Gentz R., Dixit V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818, [INFOTRIEVE], [CSA], [CROSSREF]
- Pitti R. M., Marsters S. A., Ruppert S., Donahue C. J., Moore A., Ashkenazi A. Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family. J. Biol. Chem 1996; 271(22)12687–12690, [INFOTRIEVE], [CSA], [CROSSREF]
- Radke J., Schmidt D., Bohme M., Schmidt U., Weise W., Morenz J. -Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd 1996; 56: 83–87, [INFOTRIEVE], [CSA]
- Renshaw S. A., Parmar J. S., Singleton V., Rowe S. J., Dockrell D. H., Dower S. K., Bingle C. D., Chilvers E. R., Whyte M. K. Acceleration of human neutrophil apoptosis by TRAIL. J. Immunol 2003; 170: 1027–1033, [INFOTRIEVE], [CSA]
- Rosenthal E. L., Zhang W., Talbert M., Raisch K. P., Peters G. E. Extracellular matrix metalloprotease inducer-expressing head and neck squamous cell carcinoma cells promote fibroblast-mediated type I collagen degradation in vitro. Mol. Cancer Res 2005; 3: 195–202, [INFOTRIEVE], [CSA]
- Seitz S., Wassmuth P., Fischer J., Nothnagel A., Jandrig B., Schlag P. M., Scherneck S. Mutation analysis and mRNA expression of trail-receptors in human breast cancer. Int. J. Cancer 2002; 102: 117–128, [INFOTRIEVE], [CSA], [CROSSREF]
- Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436: 568–572, [INFOTRIEVE], [CSA], [CROSSREF]
- Shiraki K., Yamanaka T., Inoue H., Kawakita T., Enokimura N., Okano H., Sugimoto K., Murata K., Nakano T. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int. J. Oncol 2005; 26: 1273–1281, [INFOTRIEVE], [CSA]
- Smyth M. J., Takeda K., Hayakawa Y., Peschon J. J., van den Brink M. R., Yagita H. Nature's TRAIL–on a path to cancer immunotherapy. Immunity 2003; 18: 1–6, [INFOTRIEVE], [CSA], [CROSSREF]
- Sonveaux P., Dessy C., Martinive P., Havaux X., Jordan B. F., Gallez B., Gregoire V., Balligand J. L., Feron O. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 2004; 64: 3209–3214, [INFOTRIEVE], [CSA], [CROSSREF]
- Sprick M. R., Rieser E., Stahl H., Grosse-Wilde A., Weigand M. A., Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. Embo J 2002; 21: 4520–4530, [INFOTRIEVE], [CSA], [CROSSREF]
- Sternlicht M. D., Lochter A., Sympson C. J., Huey B., Rougier J. P., Gray J. W., Pinkel D., Bissell M. J., Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98: 137–146, [INFOTRIEVE], [CSA], [CROSSREF]
- Sternlicht M. D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol 2001; 17: 463–516, [INFOTRIEVE], [CSA], [CROSSREF]
- Strebel A., Bachmann F., Wernli M., Erb P. Tumor necrosis factor-related, apoptosis-inducing ligand supports growth of mouse mastocytoma tumors by killing tumor-infiltrating macrophages. Int. J. Cancer 2002; 100: 627–634, [INFOTRIEVE], [CSA], [CROSSREF]
- Strieth S., Eichhorn M. E., Sauer B., Schulze B., Teifel M., Michaelis U., Dellian M. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int. J. Cancer 2004; 110: 117–124, [INFOTRIEVE], [CSA], [CROSSREF]
- Takeda K., Smyth M. J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med 2002; 195: 161–169, [INFOTRIEVE], [CSA], [CROSSREF]
- Wang G. L., Jiang B. H., Rue E. A., Semenza G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995; 92: 5510–5514, [INFOTRIEVE], [CSA], [CROSSREF]
- Westermann A. M., Beijnen J. H., Moolenaar W. H., Rodenhuis S. Growth factors in human ovarian cancer. Cancer Treat. Rev 1997; 23: 113–131, [INFOTRIEVE], [CSA], [CROSSREF]
- Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C., Nicholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A., Goodwin R. G. Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis. Immunity 1995; 3: 673–682, [INFOTRIEVE], [CSA], [CROSSREF]
- Wouters B. G., Brown J. M. Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat. Res 1997; 147: 541–550, [INFOTRIEVE], [CSA]
- Zhong H., De Marzo A. M., Laughner E., Lim M., Hilton D. A., Zagzag D., Buechler P., Isaacs W. B., Semenza G. L., Simons J. W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer. Res 1999; 59: 5830–5835, [INFOTRIEVE], [CSA]